Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30809603 | 0.90 | TACR1 (0.40) | TACR1HDAC1HDAC2GPR119MEN1 | |
| SCHEMBL25138149 | 0.89 | TACR1 (0.41) | TACR1HDAC1HDAC2GPR119MEN1 | |
| SCHEMBL21831298 | 0.89 | TACR1 (0.39) | TACR1HDAC1HDAC2GPR119MEN1 | |
| SCHEMBL30554479 | 0.88 | TACR1 (0.38) | TACR1HDAC1HDAC2GPR119MEN1 | |
| SCHEMBL23126416 | 0.88 | TACR1 (0.38) | TACR1HDAC1HDAC2GPR119MEN1 | |
| SCHEMBL21910374 | 0.87 | TACR1 (0.37) | TACR1TSHRHDAC1HDAC2GPR119 | |
| SCHEMBL30554486 | 0.87 | TACR1 (0.37) | TACR1TSHRHDAC1HDAC2GPR119 | |
| SCHEMBL21911495 | 0.85 | TACR1 (0.38) | TACR1HDAC1HDAC2GPR119MEN1 | |
| SCHEMBL29922715 | 0.85 | MAPK14 (0.44) | TACR1HDAC1HDAC2GPR119MEN1 | |
| SCHEMBL29922480 | 0.85 | MAPK14 (0.44) | TACR1HDAC1HDAC2GPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-28 | — | — | US | disclosed |
| CN-115175907-B | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| CN-115175907-A | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2022-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | TACR1 2439/4885TSHR 2365/4885HDAC1 1520/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | TACR1 2439/4885TSHR 2365/4885HDAC1 1520/4885 |
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | TACR1 1827/4885TSHR 1632/4885HDAC1 803/4885 |
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | DGKZ, DGKA, DGKG | TACR1 1827/4885TSHR 1632/4885HDAC1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.